NFKB1 and diabetes mellitus: Studies have shown that oral cysteine prevents NF-κB activation and reduces the expression of vascular inflammatory cytokines by inhibiting ROS production, improving diabetes-induced vascular inflammation in rat models of diabetes [18,47].